Diltiazem vs Amlodipine: Same Channel, Different Effects
What is the difference between diltiazem and amlodipine?
Diltiazem and amlodipine both inhibit L-type calcium channels, but their tissue effects differ. Amlodipine, a dihydropyridine, predominantly relaxes vascular smooth muscle and lowers vascular resistance. Diltiazem, a nondihydropyridine, also slows AV-nodal conduction and has negative inotropic effects. The heart rate, rhythm, blood pressure and ventricular function change the meaning of that difference.
Key takeaways
- A shared channel target does not make the drugs interchangeable.
- Amlodipine acts more strongly on vascular smooth muscle than cardiac muscle.
- Diltiazem’s conduction and contraction effects matter in heart block or decompensated heart failure.
Why does amlodipine mainly lower vascular tone?
Calcium entering vascular smooth muscle contributes to contraction. Amlodipine reduces calcium entry with a greater effect on vascular smooth muscle than on cardiac muscle. The vessel relaxes, reducing systemic vascular resistance and the load opposing ventricular ejection.
This is the basis for its antihypertensive action. It does not provide the same AV-nodal rate-control action as diltiazem. Reading only “calcium channel blocker” without identifying the drug misses a clinically useful distinction.
What does diltiazem add at the heart?
Calcium-dependent conduction is particularly relevant in nodal tissue. Diltiazem slows AV-nodal conduction and increases nodal refractoriness. It also has negative inotropic effects, meaning it reduces the strength of cardiac contraction.
Diltiazem also affects blood vessels, so this is a difference in relative tissue effects rather than an absolute heart-versus-vessel split. Its use for selected supraventricular rhythms depends on the rhythm and the patient’s condition.
What patient information belongs in the comparison?
Review the ECG and conduction, baseline heart rate, blood pressure and ventricular function. Slowing an already slow rate or worsening conduction is different from treating a rapid ventricular response. Reducing contraction is a concern in acute decompensated heart failure.
The IV diltiazem label warns against use in acute decompensated heart failure or cardiogenic shock. Pre-excited AF is another separate contraindication to AV-nodal rate-control drugs. For an interview, connect the tissue effect to the patient finding, rather than claiming both drugs accomplish the same clinical job.
